



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/071,124	02/07/2002	John M. Pezzuto	7500-0004.10	2746
23980	7590	10/30/2003	EXAMINER	
REED & EBERLE LLP 800 MENLO AVENUE, SUITE 210 MENLO PARK, CA 94025			JONES, DWAYNE C	
			ART UNIT	PAPER NUMBER
			1614	

DATE MAILED: 10/30/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application N .

10/071,124

Applicant(s)

PEZZUTO ET AL.

Examiner

Dwayne C Jones

Art Unit

1614

– The MAILING DATE of this communication appears on the cover sheet with the correspondence address –  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 13 October 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 68-92 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 68-92 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Status of Claims***

1. Claims 68-92 are pending.
2. Claims 68-92 are rejected.

### ***Response to Arguments***

3. Applicant's arguments filed August 13, 2003 have been fully considered but they are not persuasive. Applicants make the following arguments. First, applicants argue that Carson et al. fail to teach the use of resveratrol to treat the recited inflammatory skin disorders of the instant invention. Next, applicants argue that the cosmetic composition of Ashida et al. is only directed for antimicrobials, ultraviolet absorption, and skin conditions such as rough skin and malting.
4. First, applicants argue that Carson et al. fail to teach the use of resveratrol to treat the recited inflammatory skin disorders of the instant invention. In addition, applicants allege that Carson et al. do not mention whether the anti-inflammatory properties of resveratrol are derived from an oral or topical administration of the agent. Next, applicants argue that the cosmetic composition of Ashida et al. is only directed for antimicrobials, ultraviolet absorption, and skin conditions such as rough skin and malting. In fact, applicants even purport that Ashida et al. neither teach nor suggest that the resveratrol-ethanol formulation has any anti-inflammatory abilities.
5. The ensuing response will apply to both of applicants' arguments for the prior art references of Carson et al. and Ashida et al. The instant claims are composition claims, which contain resveratrol and emollients for topical use. The prior art references of

Art Unit: 1614

Carson et al. and Ashida et al. teach of composition claims that contain the very same compound of resveratrol as well as emollients. In addition, Carson et al. also teach of topical formulations that include resveratrol. Moreover, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

***Claim Rejections - 35 USC § 112***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. The rejection of claims 68-87 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating skin conditions, diseases, disorders associated with inflammation, does not reasonably provide enablement for preventing skin conditions, diseases, disorders associated with inflammation is maintained and repeated because the word "preventing" is still present in independent claim 68. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

(1) The nature of the invention:

The instant invention is directed to pharmaceutical compositions of resveratrol that are used in the prevention of skin conditions, diseases, disorders associated with inflammation.

(2) The state of the prior art

The compounds of the inventions are pharmaceuticals compositions of resveratrol. However, the prior art does not teach that these compositions possess these types of properties, see Carson et al. of U.S. Patent No. 6,270,780.

(3) The relative skill of those in the art

The relative skill of those in the art of pharmaceuticals is high.

(4) The predictability or unpredictability of the art

The unpredictability of the pharmaceutical art is very high. In fact, the courts have made a distinction between mechanical elements function the same in different circumstances, yielding predictable results, chemical and biological compounds often react unpredictably under different circumstances. Nationwide Chem. Corp. v. Wright, 458 F. Supp. 828, 839, 192 USPQ 95, 105(M.D. Fla. 1976); Aff'd 584 F.2d 714, 200 USPQ 257 (5<sup>th</sup> Cir. 1978); In re Fischer, 427 F.2d 833, 839, 166 USPQ 10, 24 (CCPA 1970). Thus, the physiological activity of a chemical or biological compound is considered to be an unpredictable art. For example, in Ex Parte Sudilovsky, the Court held that Appellant's invention directed to a method for preventing or treating a disease known as tardive dyskinesia using an angiotensin converting enzyme inhibitor involved unpredictable art because it concerned the pharmaceutical activity of the compound. 21 USPQ2d 1702, 1704-5 (BDAI 1991); In re Fisher, 427 F.2d 1557, 1562, 29 USPQ, 22 (holding that the physiological activity of compositions of adrenocorticotrophic hormones was unpredictable art); In re Wright, 999 F.2d 1557, 1562, 29 USPQ d, 1570, 1513-14 (Fed. Cir. 1993) (holding that the physiological activity of RNA viruses was unpredictable art); Ex Parte Hitzeman, 9 USPQ2d 1821, 1823 (BDAI 1987); Ex Parte Singh, 17 USPQ2d 1714, 1715, 1716 (BPAI 1990). Likewise, the physiological or pharmaceutical activity of resveratrol for the prevention of skin conditions, diseases, disorders associated with inflammation is not supported in the instant specification.

(5) The breadth of the claims

The instant claims are very broad. For instance, claim 68 is directed to the topical pharmaceutical compositions of resveratrol that are used in the prevention of skin conditions, diseases, disorders associated with inflammation. The breadth of claims was a factor in Amgen v. Chugai Pharm. Co., 927 F.2d 1200, 18 USPQ2d (Fed. Cir.), cert. Denied, 502 U.S. 856 (1991). In the Amgen case, the patent claims were directed to DNA sequences that encoded amino acid sequences. Because a very small change in the amino acid sequence of a protein can result in a very large change in the structure-function activity of a protein and because the laws of protein folding are in such a primitive state, predicting protein structure (and hence, activity) while knowing only the sequence of the protein is akin to predicting the weather for a date in the future.

(6) The amount of direction or guidance presented

The amount of guidance or direction needed to enable the invention is inversely related to the degree of predictability in the art. In re Fisher, 839, 166 USPQ 24. Thus, although a single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements, in cases involving unpredictable factors, such as most chemical reactions and physiological activity, more teaching or guidance is required. In re Fischer, 427 F.2d 839, 166 USPQ 24; Ex Parte Hitzeman, 9 USPQ 2d 1823. For example, the Federal Circuit determined that, given the unpredictability of the physiological activity of RNA viruses, a specification requires more than a general description and a single embodiment to provide an enabling

disclosure for a method of protecting an organism against RNA viruses. In re Wright, 999 F.2d 1562-63, 27 USPQ2d 1575. The specification provides no guidance, in the way of enablement for pharmaceutical compositions of resveratrol that are used in the prevention of skin conditions, diseases, disorders associated with inflammation other than employing these topical pharmaceutical compositions for the treatment of skin conditions, diseases, disorders associated with inflammation. The specification provides no guidance, in the way enablement for topical pharmaceutical compositions of resveratrol that are used in the prevention of skin conditions, diseases, and disorders associated with inflammation. In re Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 27 USPQ2d 1510 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one species, what other species will work. In re Dreshfield, 110 F.2d 235, 45 USPQ 36 (CCPA 1940), gives this general rule: "It is well settled that in cases involving chemicals and chemical compounds, which differ radically in their properties it must appear in an applicant's specification either by the enumeration of a sufficient number of the members of a group or by other appropriate language, that the chemicals or chemical combinations included in the claims are capable of accomplishing the desired result." The article "Broader than the Disclosure in Chemical Cases," 31 J.P.O.S. 5, by Samuel S. Levin covers this subject in detail. A disclosure should contain representative examples, which provide reasonable assurance to one skilled in the art that the compounds fall within the scope of a claim



will possess the alleged activity. See In re Riat et al. (CCPA 1964) 327 F2d 685, 140 USPQ 471; In re Barr et al. (CCPA 1971) 444 F 2d 349, 151 USPQ 724.

(7) The presence or absence of working examples

As stated above, the specification discloses topical pharmaceutical formulations of resveratrol that are useful in the prevention of skin conditions, diseases, disorders associated with inflammation. However, the instant specification only has enablement for the treatment of skin conditions, diseases, disorders associated with inflammation.

(8) The quantity of experimentation necessary

The quantity of experimentation needed to be performed by one skilled in the art is yet another factor involved in the determining whether "undue experimentation" is required to make and use the instant invention. "The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed." In re Wands, 858 F.2d 737, 8 USPQ2d 1404 (citing In re Angstadt, 537 F.2d 489, 502-04, 190 USPQ 214, 218 (CCPA 1976)). For these reasons, one of ordinary skill in the art would be burdened with undue "painstaking experimentation study" to determine how these topical pharmaceutical formulations of resveratrol that would be enabled in this specification.

***Claim Rejections - 35 USC § 102***

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

9. The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

10. Claims 68, 73, 74, 79-82, and 84-87 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Carson et al. of U.S. Patent No. 6,270,780, possessing an effective filing date of July 25, 1997. Carson et al. teach of topical compositions of resveratrol in amounts ranging from about 0.0002 to about 10 % by weight of the composition, (see column 4, lines 13-15). Carson et al. also teach of using various types of emollients such as polyethylene glycol as well as various other types of emollients, (see from column 5, line 49 to column 6, line 37). Carson et al. also teach that these compounds may be formulated in lotions, creams or even a gel, (see column 6, lines 50-63). The instant composition differs in the specific range of dosages claimed. The determination of a dosage having the optimum therapeutic index is well

within the purview of the skilled artisan in the art, and the artisan would be motivated to determine optimum amounts to get the maximum effect of the drug. Accordingly, Carson et al. provides the skilled artisan with the motivation to vary the amounts as well as the excipients in the topical formulation disclosed by Carson et al. In addition, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

***Claim Rejections - 35 USC § 103***

11. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

12. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

13. The rejection of claims 68-92 under 35 U.S.C. 103(a) as being unpatentable over Carson et al. of U.S. Patent No. 6,270,780, possessing an effective filing date of July 25, 1997 is maintained and repeated for both the above-stated and reasons of record. Carson et al. teach of topical compositions of resveratrol in amounts ranging from about 0.0002 to about 10 % by weight of the composition, (see column 4, lines 13-15). Carson et al. also teach of using various types of emollients such as polyethylene glycol as well as various other types of emollients, (see from column 5, line 49 to column 6, line 37). Carson et al. also teach that these compounds may be formulated in lotions, creams or a even a gel, (see column 6, lines 50-63). The instant composition differs in the specific range of dosages claimed. The determination of a dosage having the optimum therapeutic index is well within the purview of the skilled artisan in the art, and the artisan would be motivated to determine optimum amounts to get the maximum effect of the drug. Accordingly, Carson et al. provides the skilled artisan with the motivation to vary the amounts as well as the excipients in the topical formulation disclosed by Carson et al. Moreover, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative

difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

14. The rejection of claims 68-91 under 35 U.S.C. 103(a) as being unpatentable over Ashida of JP 4093288410 A, which has a publication date of December 22, 1997 is maintained and repeated for both the above-stated and reasons of record. Ashida discloses of a cosmetic formulation, which contains resveratrol in amounts ranging from about 0.001 to 5 wt. %, (see abstract). Although Ashida may be silent to the derivatives of resveratrol as well as the specific pharmaceutically acceptable excipients and emollients, it is well within the level of the skilled artisan to determine optimum amounts of the active ingredient and also with the types and amounts of the pharmaceutically acceptable excipients, diluents, emollients, etc., The determination of a dosage having the optimum therapeutic index is well within the purview of the skilled artisan in the art, and the artisan would be motivated to determine optimum amounts to get the maximum effect of the drug. Accordingly, the skilled artisan is provided with the motivation to vary the amounts as well as the excipients in the topical formulation disclosed by Ashida. Moreover, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

***Conclusion***

15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.


Application/Control Number: 10/071,124

Page 14

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.



DWAYNE C. JONES  
PRIMARY EXAMINER

Tech. Ctr. 1614

October 28, 2003